<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00786487</url>
  </required_header>
  <id_info>
    <org_study_id>0804M29862</org_study_id>
    <secondary_id>pending</secondary_id>
    <nct_id>NCT00786487</nct_id>
  </id_info>
  <brief_title>Training Effects on Skeletal Muscle Fatty Acid Metabolism</brief_title>
  <official_title>Training Effects on Skeletal Muscle Fatty Acid Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are interested in how skeletal muscle processes fat and how this may affect insulin
      resistance. This is an important question since insulin resistance predates and predicts type
      2 diabetes. We know that if pharmaceutical grade fat is infused into people, they develop
      insulin resistance. Likewise, we would like to infuse pharmaceutical grade fat into trained
      subjects, believing that trained subjects will have less insulin resistance, less decline in
      muscle energy function, and less accumulation of fat metabolites than untrained subjects. For
      comparing the effects of the pharmaceutical grade fat infusion, we will also have a group of
      trained and untrained subjects given a control (glycerol) infusion. Glycerol is basically the
      same as pharmaceutical grade fat infusion without the fat component.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We are interested in how skeletal muscle processes fat and its effect on insulin resistance.
      This is an important question since insulin resistance predates and predicts type 2 diabetes.
      We know that if pharmaceutical grade lipid is infused into people, they develop insulin
      resistance. Thus, we would like to infuse pharmaceutical grade lipid into trained subjects,
      believing that trained subjects will develop less insulin resistance, less decline in muscle
      energy function, and less accumulation of fat metabolites than untrained subjects. For
      comparing the effects of the pharmaceutical grade fat infusion, we will also have a group of
      trained and untrained subjects given a control (glycerol) infusion. Glycerol is basically the
      same as pharmaceutical grade lipid infusion without the lipid component.

      Three visits will be required. The first visit will involve measurement of fitness. A second
      visit will involve measurement of insulin resistance. The third visit will involve an
      inpatient stay, with a six hour infusion either the lipid or glycerol. Three muscle biopsies
      (before, during and after) will be take in conjunction with the infusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity as Measured by Hyperinsulinemic Euglycemic Clamp at a Single Time Point (6 Hrs) After Intralipid or Glycerol Infusion</measure>
    <time_frame>at 6 hours after starting lipid/glycerol infusion</time_frame>
    <description>Insulin sensitivity (M value: Glucose infusion rate/kg FFM/min)measured at single time point 6 hours after initiating either intralipid or glycerol infusion)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>lipid trained</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20% lipid infusion in trained subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glycerol trained</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>glycerol infusion into trained subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lipid untrained</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lipid infusion into untrained subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glycerol untrained</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>glycerol infusion into untrained subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20% lipid infusion</intervention_name>
    <description>1.5 ml/min for 6 hours</description>
    <arm_group_label>lipid trained</arm_group_label>
    <arm_group_label>lipid untrained</arm_group_label>
    <other_name>Intralipid</other_name>
    <other_name>triglyceride infusion</other_name>
    <other_name>lipid infusion</other_name>
    <other_name>fat infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glycerol</intervention_name>
    <description>glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,</description>
    <arm_group_label>glycerol trained</arm_group_label>
    <arm_group_label>glycerol untrained</arm_group_label>
    <other_name>Control infusion</other_name>
    <other_name>glycerol infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Regardless of training status, age range will be from age 18 to 45. We will be
             limiting the upper age range because increased age is associated with sarcopenia and
             alteration of fiber type 29 and we would like to limit the confounding effects of age.

          -  We will define the lean group by a BMI of &lt; 25 kg/m2. Weight must be stable [+/- 5
             pounds] for at least the three months prior to the study for all participants.

          -  The untrained subjects must not be engaged in a regular exercise program (&lt; 30 minutes
             regular exercise over 1 week).

          -  The trained subjects should be participating in regular running exercise (&gt; 45
             min/day, â‰¥ 5 days/week) and preferably be currently or recently participating in
             competitions (within 2 years).

        Exclusion Criteria:

          -  Regardless of training status, subjects must not be on medications that may affect
             lipid levels, specifically lipid lowering agents, birth control pills or diuretics.

          -  The subjects should not be on a high fat diet (&gt; 45% fat) as measured by a screening
             questionnaire. We will also administer a PAR-Q questionnaire (attached) to establish
             whether the subject will be safe for exercise testing. - The female subjects must not
             be pregnant. A pregnancy test will be performed prior to all study visits.

          -  If screening TG are &gt; 300 (based on 1st visit results) or fasting glucose &gt; 100 (based
             on 1st visit results), the subjects will be excluded.

          -  If the subject is allergic to eggs (used in lipid emulsions), soybeans(used in lipid
             emulsions), or lipid emulsions the subject will be excluded from the study.

          -  Subjects taking anti-platelet agents (if anti-platelet agent cannot be held for seven
             days) and subjects taking anticoagulation therapy will be excluded.

          -  Subjects with clinically significant medical issues or a history of hematologic
             (platelets &lt; 100), hepatic (LFTs &gt; 2X nl), renal (Cr &gt; 1.5), pulmonary, or cardiac
             abnormalities (including abnormal EKG) will also be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa S Chow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2008</study_first_submitted>
  <study_first_submitted_qc>November 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2008</study_first_posted>
  <results_first_submitted>May 29, 2015</results_first_submitted>
  <results_first_submitted_qc>July 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 23, 2015</results_first_posted>
  <last_update_submitted>July 22, 2015</last_update_submitted>
  <last_update_submitted_qc>July 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>insulin resistance</keyword>
  <keyword>lipid metabolism</keyword>
  <keyword>lipid infusion</keyword>
  <keyword>glycerol infusion</keyword>
  <keyword>skeletal muscle</keyword>
  <keyword>diabetes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>we had anticipated enrollment of 36 subjects but ended up finishing the study with 33 subjects</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lipid Trained</title>
          <description>20% lipid infusion in trained subjects
20% lipid infusion: 1.5 ml/min for 6 hours</description>
        </group>
        <group group_id="P2">
          <title>Glycerol Trained</title>
          <description>glycerol infusion into trained subjects
glycerol: glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,</description>
        </group>
        <group group_id="P3">
          <title>Lipid Untrained</title>
          <description>lipid infusion into untrained subjects
20% lipid infusion: 1.5 ml/min for 6 hours</description>
        </group>
        <group group_id="P4">
          <title>Glycerol Untrained</title>
          <description>glycerol infusion into untrained subjects
glycerol: glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lipid Trained</title>
          <description>20% lipid infusion in trained subjects
20% lipid infusion: 1.5 ml/min for 6 hours</description>
        </group>
        <group group_id="B2">
          <title>Glycerol Trained</title>
          <description>glycerol infusion into trained subjects
glycerol: glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,</description>
        </group>
        <group group_id="B3">
          <title>Lipid Untrained</title>
          <description>lipid infusion into untrained subjects
20% lipid infusion: 1.5 ml/min for 6 hours</description>
        </group>
        <group group_id="B4">
          <title>Glycerol Untrained</title>
          <description>glycerol infusion into untrained subjects
glycerol: glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" spread="6"/>
                    <measurement group_id="B2" value="24" spread="3"/>
                    <measurement group_id="B3" value="21" spread="2"/>
                    <measurement group_id="B4" value="21" spread="2"/>
                    <measurement group_id="B5" value="23" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>insulin sensitivity</title>
          <units>M value</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.5" spread="3.5"/>
                    <measurement group_id="B2" value="12" spread="3"/>
                    <measurement group_id="B3" value="7" spread="1.6"/>
                    <measurement group_id="B4" value="9" spread="3"/>
                    <measurement group_id="B5" value="10.7" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity as Measured by Hyperinsulinemic Euglycemic Clamp at a Single Time Point (6 Hrs) After Intralipid or Glycerol Infusion</title>
        <description>Insulin sensitivity (M value: Glucose infusion rate/kg FFM/min)measured at single time point 6 hours after initiating either intralipid or glycerol infusion)</description>
        <time_frame>at 6 hours after starting lipid/glycerol infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lipid Trained</title>
            <description>20% lipid infusion in trained subjects
20% lipid infusion: 1.5 ml/min for 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Glycerol Trained</title>
            <description>glycerol infusion into trained subjects
glycerol: glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,</description>
          </group>
          <group group_id="O3">
            <title>Lipid Untrained</title>
            <description>lipid infusion into untrained subjects
20% lipid infusion: 1.5 ml/min for 6 hours</description>
          </group>
          <group group_id="O4">
            <title>Glycerol Untrained</title>
            <description>glycerol infusion into untrained subjects
glycerol: glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity as Measured by Hyperinsulinemic Euglycemic Clamp at a Single Time Point (6 Hrs) After Intralipid or Glycerol Infusion</title>
          <description>Insulin sensitivity (M value: Glucose infusion rate/kg FFM/min)measured at single time point 6 hours after initiating either intralipid or glycerol infusion)</description>
          <units>M value</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="3"/>
                    <measurement group_id="O2" value="12" spread="2"/>
                    <measurement group_id="O3" value="6" spread="2"/>
                    <measurement group_id="O4" value="11" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lipid Trained</title>
          <description>20% lipid infusion in trained subjects
20% lipid infusion: 1.5 ml/min for 6 hours</description>
        </group>
        <group group_id="E2">
          <title>Glycerol Trained</title>
          <description>glycerol infusion into trained subjects
glycerol: glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,</description>
        </group>
        <group group_id="E3">
          <title>Lipid Untrained</title>
          <description>lipid infusion into untrained subjects
20% lipid infusion: 1.5 ml/min for 6 hours</description>
        </group>
        <group group_id="E4">
          <title>Glycerol Untrained</title>
          <description>glycerol infusion into untrained subjects
glycerol: glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>numbness</sub_title>
                <description>slight skin numbness at site of muscle biopsy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Lisa Chow</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-625-8934</phone>
      <email>chow0007@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

